GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abbott Laboratories (Pakistan) Ltd (KAR:ABOT) » Definitions » Research & Development

Abbott Laboratories (Pakistan) (KAR:ABOT) Research & Development : ₨41 Mil (TTM As of Mar. 2024)


View and export this data going back to 1982. Start your Free Trial

What is Abbott Laboratories (Pakistan) Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Abbott Laboratories (Pakistan)'s Research & Development for the three months ended in Mar. 2024 was ₨19 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ₨41 Mil.


Abbott Laboratories (Pakistan) Research & Development Historical Data

The historical data trend for Abbott Laboratories (Pakistan)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories (Pakistan) Research & Development Chart

Abbott Laboratories (Pakistan) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.36 63.07 84.95 62.09 24.94

Abbott Laboratories (Pakistan) Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 3.66 3.64 15.14 18.75

Abbott Laboratories (Pakistan) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbott Laboratories (Pakistan)  (KAR:ABOT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Abbott Laboratories (Pakistan) Research & Development Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories (Pakistan)'s Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Pakistan) (KAR:ABOT) Business Description

Traded in Other Exchanges
N/A
Address
Hyderabad Road, Landhi, P.O. Box 7229, Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Karachi, PAK, 75120
Abbott Laboratories (Pakistan) Ltd is engaged in manufacturing, importing, and marketing research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and also has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. Its Brands include Duphaston, Surbex Z, Serc, Duphala, Pediasur, Similac, and others.

Abbott Laboratories (Pakistan) (KAR:ABOT) Headlines

No Headlines